Now ideas for wellness

About Meiji

At a Glance

At a Glance

Get to know Meiji at a glance – from our core business to our most important numbers.

CNS Disorders

an image of the nervous system

Modern medicine recognizes a growing number of mental disorders linked to the central nervous system (CNS). Meiji has decades of expertise in this field, launching some of Japan's earliest antidepressants and anti-anxiety drugs, including the first selective serotonin reuptake inhibitor in 1999.  

Therapeutic Areas

  • Schizophrenia

  • Depression

  • Dravet syndrome

  • Insomnia

  • Panic disorder

  • Post-traumatic stress disorder

  • Obsessive-compulsive disorder

  • a photo of a family
  • Our Approach to Rare and Common CNS Disorders

    CNS disorders are on the rise due to factors such as aging, lifestyle changes, and stress. Effectively treating such a wide range of conditions is a challenge for many societies. Meiji Seika Pharma's primary focus is on new treatments for depression and schizophrenia, as well as Dravet syndrome, a rare form of epilepsy of unknown cause. At the same time, the company supplies generic drugs for widespread conditions such as Alzheimer's.

    * Image used for illustration purposes only.